# A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

> **NCT00533702** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 106 (actual)

## Conditions studied

- Metastatic Malignant Melanoma

## Interventions

- **BIOLOGICAL:** IMC-1121B (ramucirumab)
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT00533702
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2014-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00533702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00533702, "A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00533702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*